Table of Contents

company-logo

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

ProQR Therapeutics Dividend Announcement

• ProQR Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on ProQR Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

ProQR Therapeutics Dividend History

ProQR Therapeutics Dividend Yield

ProQR Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing ProQR Therapeutics stock? Use our calculator to estimate your expected dividend yield:

ProQR Therapeutics Financial Ratios

P/E ratio-11.60
PEG ratio9.94
P/B ratio11.07
ROE-71.11%
Payout ratio0.00%
Current ratio2.33
Quick ratio2.33
Cash Ratio2.26

ProQR Therapeutics Dividend FAQ

Does ProQR Therapeutics stock pay dividends?
ProQR Therapeutics does not currently pay dividends to its shareholders.
Has ProQR Therapeutics ever paid a dividend?
No, ProQR Therapeutics has no a history of paying dividends to its shareholders. ProQR Therapeutics is not known for its dividend payments.
Why doesn't ProQR Therapeutics pay dividends?
There are several potential reasons why ProQR Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will ProQR Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While ProQR Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is ProQR Therapeutics a dividend aristocrat?
ProQR Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is ProQR Therapeutics a dividend king?
ProQR Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is ProQR Therapeutics a dividend stock?
No, ProQR Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy ProQR Therapeutics stocks?
To buy ProQR Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy ProQR Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.